Core Viewpoint - Ipsen has voluntarily withdrawn Tazverik (tazemetostat) from all markets due to emerging safety concerns regarding secondary hematologic malignancies, as advised by the Independent Data Monitoring Committee (IDMC) [1][3] Group 1: Withdrawal Details - The withdrawal of Tazverik affects all indications, including follicular lymphoma (FL) and epithelioid sarcoma (ES), and is effective immediately [1] - Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial, transitioning them to standard care with lenalidomide plus rituximab [2] - All active tazemetostat clinical trials and expanded access programs are being discontinued [2] Group 2: Clinical Trial Information - The SYMPHONY-1 trial is a global Phase Ib/III study evaluating Tazverik in combination with lenalidomide and rituximab as a second-line therapy for relapsed/refractory follicular lymphoma [7] - The trial spans 229 sites across 15 countries, including the U.S., EU, and China, and includes analyses for both EZH2-wild-type and EZH2-mutant patient populations [8] Group 3: Regulatory and Market Impact - Ipsen is collaborating with the U.S. Food and Drug Administration (FDA) to execute the withdrawal and provide necessary information [3] - Tazverik received accelerated approval from the FDA in 2020 for specific patient populations, including adults with relapsed or refractory FL and those with metastatic or locally advanced epithelioid sarcoma [3][5] - The withdrawal is not expected to impact the company's financial guidance [4]

Core Viewpoint - HUTCHMED is withdrawing TAZVERIK from the Chinese market following Ipsen's voluntary withdrawal in the US due to safety concerns related to secondary hematologic malignancies observed in clinical trials [1][2][3] Group 1: Product Withdrawal and Clinical Trials - Ipsen has informed HUTCHMED of the immediate withdrawal of TAZVERIK, affecting both follicular lymphoma and epithelioid sarcoma treatments [2][3] - HUTCHMED has initiated a market withdrawal and product recall in China, Hong Kong, and Macau, and is discontinuing all active clinical trials involving tazemetostat [1][4] - Existing patients are advised to consult their healthcare providers regarding alternative treatment options [1] Group 2: Regulatory and Safety Measures - HUTCHMED has promptly notified healthcare professionals and regulatory authorities, including the China National Medical Products Administration, about the withdrawal [4] - The company has suspended all sales and shipments of TAZVERIK and instructed healthcare institutions to cease prescribing it [4] Group 3: Financial Impact - The withdrawal of TAZVERIK is not expected to impact HUTCHMED's financial guidance, with reported sales of TAZVERIK at US$2.5 million in 2025 [6] Group 4: Background on TAZVERIK - TAZVERIK is a first-in-class methyltransferase inhibitor of EZH2, initially approved by the US FDA in 2020 under the accelerated approval program [5] - The drug received conditional approval from the NMPA for treating follicular lymphoma as an imported drug, subject to ongoing regulatory obligations [5] Group 5: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7]

Core Viewpoint - Ipsen has voluntarily withdrawn Tazverik (tazemetostat) from all markets due to emerging safety concerns related to secondary hematologic malignancies, as advised by the Independent Data Monitoring Committee (IDMC) [1][3] Withdrawal Details - The withdrawal of Tazverik affects all indications, including follicular lymphoma (FL) and epithelioid sarcoma (ES), and is effective immediately [1] - Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial, transitioning them to standard care with lenalidomide plus rituximab [2] - All active tazemetostat clinical trials and expanded access programs are being discontinued [2] Clinical Trial Information - The SYMPHONY-1 trial is a global Phase Ib/III study evaluating Tazverik in combination with lenalidomide and rituximab as a second-line therapy for relapsed/refractory follicular lymphoma [7] - The trial spans 229 sites across 15 countries, including the U.S., EU, and China, and includes analyses for both EZH2-wild-type and EZH2-mutant patient populations [8] Regulatory and Market Impact - Ipsen is collaborating with the U.S. Food and Drug Administration (FDA) to execute the withdrawal and provide necessary information [3] - Tazverik received accelerated approval from the FDA in 2020 for specific patient populations, including adults with relapsed or refractory FL and those with metastatic or locally advanced epithelioid sarcoma [3][5] Financial Guidance - The withdrawal of Tazverik is not expected to impact the company's financial guidance [4]

Group 1 - Intercept Pharmaceuticals is voluntarily withdrawing its liver disease treatment from the U.S. market [1] - The withdrawal follows a request from the Food and Drug Administration [1]